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2011-2012 Influenza Season 
Week 20 ending May 19, 2012 
All data are preliminary and may change as more reports are received. 
 
Synopsis: During week 20 (May 13-19, 2012), influenza activity declined nationally and in most 
regions, but remained elevated in some areas of the United States. 
o U.S. Virologic Surveillance: Of the 2,054 specimens tested by U.S. World Health 
Organization (WHO) and National Respiratory and Enteric Virus Surveillance System 
(NREVSS) collaborating laboratories and reported to CDC/Influenza Division, 286 (13.9%) 
were positive for influenza. 
o Pneumonia and Influenza (P&I) Mortality Surveillance: The proportion of deaths 
attributed to P&I was below the epidemic threshold.  
o Influenza-Associated Pediatric Mortality: Two influenza-associated pediatric deaths were 
reported. One was associated with a seasonal influenza A (H3) virus and one was 
associated with an influenza B virus. 
o Outpatient Illness Surveillance: The proportion of outpatient visits for influenza-like illness 
(ILI) was 1.0%, which is below the national baseline of 2.4%. All regions reported ILI below 
region-specific baseline levels. One state experienced low ILI activity; New York City and 48 
states experienced minimal ILI activity, and the District of Columbia and 1 state had 
insufficient data to calculate ILI activity. 
o Geographic Spread of Influenza: One state reported widespread geographic activity; 2 
states reported regional influenza activity; 8 states reported local activity; the District of 
Columbia, Guam, Puerto Rico, and 30 states reported sporadic activity; the U.S. Virgin 
Islands and 8 states reported no influenza activity, and one state did not report. 
 
National and Regional Summary of Select Surveillance Components 
 Data for current week Data cumulative since October 2, 2011 (Week 40) 
HHS 
Surveillance 
Regions* 
Out-
patient 
ILI† 
% of 
respiratory 
specimens 
positive for 
flu‡ 
Number of  
jurisdictions 
reporting 
regional or 
widespread 
activity§  
A (H3) 2009 H1N1 
A 
(Subtyping 
not perfor-
med) 
B  Pediatric Deaths 
Nation Normal 13.9% 3 of 54 10,911 3,949 4,302 3,038 26 
Region 1 Normal 15.0% 1 of 6 428 105 97 125 0 
Region 2 Normal 24.6% 1 of 4 299 226 168 180 2 
Region 3 Normal 20.2% 0 of 6 888 162 219 343 1 
Region 4 Normal 13.6% 0 of 8 597 247 1,425 436 4 
Region 5 Normal 27.1% 0 of 6 2,751 202 142 312 1 
Region 6 Normal 4.3% 0 of 5 310 455 902 223 5 
Region 7 Normal 3.6% 0 of 4 1,386 161 256 55 1 
Region 8 Normal 10.7% 0 of 6 1,579 1,112 665 110 0 
Region 9 Normal 23.3% 0 of 5 1,819 875 393 457 11 
Region 10 Normal 27.4% 1 of 4 854 404 35 797 1 
*HHS regions (Region 1 CT, ME, MA, NH, RI, VT; Region 2: NJ, NY, Puerto Rico, U.S. Virgin Islands; Region 3: DE, DC, MD, PA, VA, WV; Region 4: AL, FL, GA, KY, MS, NC, 
SC, TN; Region 5: IL, IN, MI, MN, OH, WI; Region 6: AR, LA, NM, OK, TX; Region 7: IA, KS, MO, NE; Region 8: CO, MT, ND, SD, UT, WY; Region 9: AZ, CA, Guam, HI, NV; 
and Region 10: AK, ID, OR, WA). 
† Elevated means the % of visits for ILI is at or above the national or region-specific baseline. 
‡ National data are for current week; regional data are for the most recent three weeks. 
§ Includes all 50 states, the District of Columbia, Guam, Puerto Rico, and the U.S. Virgin Islands. 
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U.S. Virologic Surveillance: WHO and NREVSS collaborating laboratories located in all 50 states 
report to CDC the number of respiratory specimens tested for influenza and the number positive by 
influenza type and subtype. The results of tests performed during the current week are summarized 
in the table below. 
 
 Week 20 
No. of specimens tested 2,054 
No. of positive specimens (%) 286 (13.9%) 
Positive specimens by type/subtype  
Influenza A 150 (52.4%) 
          2009 H1N1   21 (14.0%)  
          Subtyping not performed          41 (27.3%)
          (H3)                88 (58.7%)  
Influenza B 136 (47.6%) 
 
Predominant influenza viruses can vary by region and even between states within the same region. 
Seasonal influenza A (H3) viruses have predominated since the start of the 2011-2012 season 
nationally and in most regions; however, in recent weeks the proportion of influenza B viruses has 
been increasing. The timing of influenza activity also can vary by region. While influenza activity 
may have peaked and be declining, or have already returned to summer baseline levels in some 
states or regions, it may be ongoing in other areas.  Region specific data can be found at 
http://gis.cdc.gov/grasp/fluview/fluportaldashboard.html. Influenza viruses circulate year-round and 
activity may persist as late as May. 
 
Influenza Positive Tests Reported to CDC by U.S. WHO/NREVSS 
Collaborating Laboratories, National Summary, 2011-2012 Season 
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Antigenic Characterization: CDC has antigenically characterized 1,816 influenza viruses [527 
2009 H1N1 viruses, 987 influenza A (H3N2) viruses, and 302 influenza B viruses] collected by U.S. 
laboratories since October 1, 2011.   
 
2009 H1N1 [527] 
• Five hundred three (95.4%) of the 527 viruses were characterized as 
A/California/7/2009-like, the influenza A (H1N1) component of the 2011-2012 
influenza vaccine for the Northern Hemisphere.  
• Twenty-four viruses (4.6%) tested showed reduced titers with antiserum produced 
against A/California/7/2009. 
 
Influenza A (H3N2) [987] 
• Eight hundred two (81.3%) of the 987 viruses were characterized as 
A/Perth/16/2009-like, the influenza A (H3N2) component of the 2011-2012 influenza 
vaccine for the Northern Hemisphere. 
• One hundred eighty-five viruses (18.7%) tested showed reduced titers with 
antiserum produced against A/Perth/16/2009. 
Influenza B (B/Victoria/02/87 and B/Yamagata/16/88 lineages) [302]: 
• Victoria Lineage [147]: One hundred forty-seven (48.7%) of the 302 influenza B 
viruses tested belong to the B/Victoria lineage of viruses.  
o One hundred thirty-nine (94.6%) of these 147 viruses were characterized as 
B/Brisbane/60/2008-like, the influenza B component of the 2011-2012 
Northern Hemisphere influenza vaccine.  
o Eight (5.4%) of these 147 viruses showed reduced titers with antisera 
produced against B/Brisbane/60/2008. 
• Yamagata Lineage [155]: One hundred fifty-five (51.3%) of the 302 influenza B 
viruses tested belong to the B/Yamagata lineage of viruses.  
While influenza B viruses account for only 14% of influenza positive tests reported to CDC this 
season, the proportion of influenza positives that are Type B has been increasing in recent weeks, 
and less than 50% of U.S. influenza B viruses tested this season are similar to the influenza B 
component in the 2011-2012 influenza vaccine. Worldwide, the majority of influenza B viruses 
circulating have been similar to the influenza B component of the 2011-2012 Northern Hemisphere 
influenza vaccine.    
 
 
Composition of the 2012-2013 Influenza Vaccine:  The World Health Organization (WHO) has 
recommended vaccine viruses for the 2012-2013 Northern Hemisphere influenza vaccines, and 
FDA’s Vaccines and Related Biological Products Advisory Committee (VRBPAC) has made 
recommendations for the composition of the 2012-2013 U.S. influenza vaccines. Both agencies 
recommend that the vaccine contain A/California/7/2009-like (2009 H1N1), A/Victoria/361/2011-like 
(H3N2), and B/Wisconsin/1/2010-like (B/Yamagata lineage) viruses. This recommendation changes 
the influenza A (H3N2) and influenza B virus components of the 2011-2012 Northern Hemisphere 
vaccine formulation. This recommendation was based on global influenza virus surveillance data 
related to epidemiology and antigenic characteristics, serological responses to 2011-2012 trivalent 
seasonal vaccines, and the availability of candidate strains and reagents. 
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Antiviral Resistance: Testing of 2009 H1N1, influenza A (H3N2), and influenza B virus isolates for 
resistance to the neuraminidase inhibitors (oseltamivir and zanamivir) is performed at CDC using a 
functional assay. Additional 2009 H1N1 clinical samples are tested for a single mutation in the 
neuraminidase of the virus known to confer oseltamivir resistance (H275Y). The data summarized 
below combine the results of both testing methods. These samples are routinely obtained for 
surveillance purposes rather than for diagnostic testing of patients suspected to be infected with an 
antiviral resistant virus. 
High levels of resistance to the adamantanes (amantadine and rimantadine) persist among 2009 
H1N1 and A (H3N2) viruses (the adamantanes do not have activity against influenza B viruses). As 
a result of the sustained high levels of resistance among circulating influenza A viruses, data from 
adamantane resistance testing are not presented in the table below.    
Neuraminidase Inhibitor Resistance Testing Results  
on Samples Collected Since October 1, 2011. 
 
Oseltamivir Zanamivir 
Virus 
Samples 
Tested (n)* 
Resistant 
Viruses, 
Number (%) 
Virus 
Samples 
Tested (n) 
Resistant 
Viruses, 
Number (%) 
Influenza A 
(H3N2) 1,275 0 (0.0) 1,275 0 (0.0) 
Influenza B 317 0 (0.0) 317 0 (0.0) 
2009 H1N1 1,164 16 (1.4) 518 0 (0.0) 
*Includes specimens tested in national surveillance and additional specimens tested at public health 
laboratories in nine states (DE, FL, MD, MI, MN, NY, TX, WA, and WI) who share testing results with 
CDC. 
 
So far this season, 16 oseltamivir-resistant 2009 H1N1 viruses have been detected nationally. 
Three patients were using oseltamivir for 1 day or more at the time of specimen collection. Thirteen 
had no exposure to oseltamivir; out of those 13 patients, 2 had family members using oseltamivir. 
(Resistance of influenza A viruses to antiviral drugs can occur spontaneously or emerge during the 
course of antiviral treatment or antiviral exposure). 
 
Eleven of the 16 oseltamivir-resistant viruses were collected from January to April 2012 and are 
from Texas, where a total of 419 2009 H1N1 specimens have been tested for oseltamivir 
resistance. Oseltamivir resistance remains quite low nationally and in Texas, even though the 
percentage of oseltamivir-resistant 2009 H1N1 viruses in Texas (2.6%) is higher than the national 
percentage. CDC continues to recommend the use of oseltamivir or zanamivir as early as possible 
for patients with confirmed or suspected influenza who have severe, complicated, or progressive 
illness; who require hospitalization; or who are at greater risk for influenza-related complications.  
Use of the adamantanes is not recommended. 
 
Additional information on recommendations for treatment and chemoprophylaxis of influenza virus 
infection with antiviral agents is available at http://www.cdc.gov/flu/antivirals/index.htm.   
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Pneumonia and Influenza (P&I) Mortality Surveillance: During week 20, 6.4% of all deaths 
reported through the 122-Cities Mortality Reporting System were due to P&I. This percentage was 
below the epidemic threshold of 7.4% for week 20. 
 
Pneumonia and Influenza Mortality for 122 U.S. Cities 
Week ending May 19, 2012 
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Influenza-Associated Pediatric Mortality: Two influenza-associated pediatric deaths were 
reported to CDC during week 20. One was associated with a seasonal influenza A (H3) virus and 
one was associated with an influenza B virus. The deaths reported during week 20 occurred during 
the week ending May 12, 2012 (week 19). This brings the total number of influenza-associated 
pediatric deaths reported during the 2011-2012 season to 26. Additional data can be found at: 
http://gis.cdc.gov/GRASP/Fluview/PedFluDeath.html. 
 
 
Number of Influenza-Associated Pediatric Deaths by Week of Death: 
2008-09 season to present 
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Influenza-Associated Hospitalizations: The Influenza Surveillance Network (FluSurv-NET) 
conducts population-based surveillance for laboratory-confirmed influenza-related hospitalizations 
in children younger than 18 years of age (since the 2003-2004 influenza season) and adults (since 
the 2005-2006 influenza season).   
   
The FluSurv-NET covers more than 80 counties in the 10 Emerging Infections Program (EIP) states 
(CA, CO, CT, GA, MD, MN, NM, NY, OR, TN) and additional Influenza Hospitalization Surveillance 
Project (IHSP) states. The IHSP began during the 2009-2010 season to enhance surveillance 
during the 2009 H1N1 pandemic. IHSP sites included IA, ID, MI, OK and SD during the 2009-2010 
season; ID, MI, OH, OK, RI, and UT during the 2010-2011 season; and MI, OH, RI, and UT during 
the 2011-2012 season. The rates provided are likely to be a vast underestimate of the actual 
number of influenza-related hospitalizations. First, the FluSurv-NET is not nationally representative, 
and second, influenza-related hospitalizations can be missed, either because testing is not 
performed, or because cases may be attributed to other causes of pneumonia or other common 
influenza-related complications. 
 
Between October 1, 2011 and April 30, 2012, 2,374 laboratory-confirmed influenza-associated 
hospitalizations were reported at a rate of 8.6 per 100,000 population. Among cases, 2,052 (86.4%) 
were influenza A, 301 (12.7%) were influenza B, and 7 (0.3%) were influenza A and B co-infections; 
14 (0.6%) had no virus type information. Among those with influenza A subtype information, 909 
(74.8%) were H3N2 and 300 (24.7%) were 2009 H1N1. The most commonly reported underlying 
medical conditions among adults were chronic lung diseases (of which 54.9% were asthma), 
cardiovascular disease and metabolic disorders. The most commonly reported underlying medical 
conditions in children were chronic lung diseases (of which 75.3% were asthma) and neurologic 
disorders. However, almost half of hospitalized children had no identified underlying medical 
conditions. 
 
The current season’s influenza-associated hospitalization data includes patients admitted from 
October 1, 2011 through April 30, 2012; however, these data will continue to be updated as 
additional information is received. 
Data from the Influenza Surveillance Network (FluSurv-NET), a population-based surveillance for influenza related 
hospitalizations in children and adults in 14 US states.  Incidence rates are calculated using the National Center for Health
Statistics’ (NCHS) population estimates for the counties included in the surveillance catchment area.  
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Selected underlying medical conditions1,2 among laboratory-confirmed 
influenza-associated hospitalizations, FluSurv-NET, 2011-20123
  
1Asthma includes a diagnosis of asthma or reactive airway disease; Chronic lung diseases include asthma as well as 
other conditions such as bronchiolitis obliterans, chronic aspiration pneumonia, and interstitial lung disease. 
Cardiovascular diseases include conditions such as coronary heart disease, cardiac valve disorders, congestive heart 
failure, pulmonary hypertension, and aortic stenosis; Immune suppression includes conditions such as immunoglobulin 
deficiency, leukemia, lymphoma, HIV/AIDS, and individuals taking immunosuppressive medications; Metabolic disorders 
include conditions such as diabetes mellitus, thyroid dysfunction, adrenal insufficiency, and liver disease; Neurologic 
diseases include conditions such as seizure disorders, cerebral palsy, and cognitive dysfunction; Neuromuscular diseases 
include conditions such as multiple sclerosis and muscular dystrophy; Obesity was assigned if indicated in patient’s 
medical chart or if body mass index (BMI) >30 kg/m2; Renal diseases include conditions such as acute or chronic renal 
failure, nephrotic syndrome, glomerulonephritis, and impaired creatinine clearance. 
2Note that asthma is included in both “Asthma” and “Chronic lung disease”; otherwise the categories are mutually 
exclusive. 
3Only includes cases for which data collection has been completed through the medical chart review stage. 
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Outpatient Illness Surveillance: Nationwide during week 20, 1.0% of patient visits reported 
through the U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet) were due to 
influenza-like illness (ILI). This percentage is below the national baseline of 2.4%. (ILI is defined as 
fever (temperature of 100°F [37.8°C] or greater) and cough and/or sore throat.) 
 
Percentage of Visits for Influenza-like Illness (ILI) Reported by  
the U.S. Outpatient Influenza-like Illness Surveillance Network (ILINet), 
Weekly National Summary, September 30, 2008 – May 19, 2012 
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On a regional level, the percentage of outpatient visits for ILI ranged from 0.2% to 1.9% during 
week 20. All regions reported a proportion of outpatient visits for ILI below region-specific baseline 
levels.   
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Region 2 - NJ, NY, USVI
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Region 3 - DE, DC, MD, PA, VA, WV
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Region 5 - IL, IN, MI, MN, OH, WI
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Region 7 - IA, KS, MO, NE
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Region 8 - CO, MT, ND, SD, UT, WY
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ILINet State Activity Indicator Map: Data collected in ILINet are used to produce a measure of ILI 
activity* by state. Activity levels are based on the percent of outpatient visits in a state due to ILI 
and are compared to the average percent of ILI visits that occur during spring and fall weeks with 
little or no influenza virus circulation. Activity levels range from minimal, which corresponds to ILI 
activity being below average, to intense, which corresponds to ILI activity being much higher than 
average. Because the clinical definition of ILI is very general, not all ILI is caused by influenza 
viruses; however, when combined with laboratory data, the information on ILI activity provides a 
clearer picture of influenza activity in the United States. 
 
During week 20, the following ILI activity levels were experienced: 
 One state experienced low ILI activity (Alabama). 
 New York City and 48 states experienced minimal ILI activity (Alaska, Arizona, Arkansas, 
California, Colorado, Connecticut, Delaware, Florida, Georgia, Hawaii, Illinois, Idaho, 
Indiana, Iowa, Kansas, Kentucky, Louisiana, Maine, Maryland, Massachusetts, Michigan, 
Minnesota, Mississippi, Missouri, Montana, Nebraska, Nevada, New Hampshire, New 
Jersey, New Mexico, New York, North Carolina, North Dakota, Ohio, Oklahoma, Oregon, 
Pennsylvania, Rhode Island, South Carolina, Tennessee, Texas, Utah, Vermont, Virginia, 
Washington, West Virginia, Wisconsin, and Wyoming). 
 Data were insufficient to calculate an ILI activity level from the District of Columbia and 1 
state (South Dakota). 
 
*This map uses the proportion of outpatient visits to health care providers for influenza-like illness to measure the ILI activity level within a 
state. It does not, however, measure the extent of geographic spread of influenza viruses within a state. Therefore, outbreaks occurring 
in a single city could cause the state to display high activity levels. 
Data collected in ILINet may disproportionally represent certain populations within a state, and therefore, may not accurately depict the 
full picture of influenza activity for the whole state. 
Data displayed in this map are based on data collected in ILINet, whereas the State and Territorial influenza activity map is based on 
reports from state and territorial epidemiologists. The data presented in this map is preliminary and may change as more data is 
received. 
Differences in the data presented here by CDC and independently by some state health departments likely represent differing levels of 
data completeness with data presented by the state likely being the more complete.   
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Geographic Spread of Influenza as Assessed by State and Territorial Epidemiologists: The 
influenza activity reported by state and territorial epidemiologists indicates geographic spread of 
influenza viruses, but does not measure the intensity of influenza activity. 
 
During week 20, the following influenza activity was reported: 
 Widespread influenza activity was reported by 1 state (New York). 
 Regional influenza activity was reported by 2 states (Alaska and Connecticut). 
 Local influenza activity was reported by 8 states (Alabama, Arizona, California, 
Massachusetts, Mississippi, Nevada, Oregon, and Washington). 
 Sporadic influenza activity was reported by the District of Columbia, Guam, Puerto Rico, and 
30 states (Colorado, Delaware, Florida, Hawaii, Indiana, Iowa, Kentucky, Louisiana, Maine, 
Maryland, Michigan, Minnesota, Missouri, Montana, New Hampshire, New Mexico, North 
Carolina, North Dakota, Ohio, Pennsylvania, Rhode Island, South Carolina, South Dakota, 
Texas, Utah, Vermont, Virginia, West Virginia, Wisconsin and Wyoming). 
 The U.S. Virgin Islands and 8 states (Arkansas, Georgia, Idaho, Illinois, Kansas, Nebraska, 
Oklahoma, and Tennessee) reported no influenza activity. 
 One state (New Jersey) did not report. 
 
 
A description of surveillance methods is available at: http://www.cdc.gov/flu/weekly/overview.htm 
Report prepared: May 25, 2012. 
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Additional National and International Influenza Surveillance Information 
 
Google Flu Trends: Google Flu Trends uses aggregated Google search data in a model created in 
collaboration with CDC to estimate influenza activity in the United States. For more information and 
activity estimates from the U.S. and worldwide, see http://www.google.org/flutrends/. 
 
Europe: For the most recent influenza surveillance information from Europe, please see 
WHO/Europe at http://www.euroflu.org/index.php and visit the European Centre for Disease 
Prevention and Control at 
http://ecdc.europa.eu/en/publications/surveillance_reports/influenza/Pages/weekly_influenza_survei
llance_overview.aspx. 
 
Public Health Agency of Canada: The most up to date influenza information from Canada is 
available at http://www.phac-aspc.gc.ca/fluwatch/. 
 
World Health Organization FluNet: Additional influenza surveillance information from participating 
WHO member nations is available through FluNet and the Global Epidemiology Reports. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
  
 
